The FDA has approved a new drug called Mavenclad (cladribine) for adults with relapsing forms of multiple sclerosis (MS). This includes relapsing-remitting MS and active secondary progressive MS. Mavenclad is a type of medicine called a purine antimetabolite. It works by reducing the number of certain immune cells that can attack the nervous system.
Mavenclad is not a first-line treatment. It is meant for people who have not had good results with other MS therapies or who cannot take them due to side effects. The approval is based on studies showing that Mavenclad can reduce relapses and slow down disability progression.
However, Mavenclad has serious risks. It carries a boxed warning about an increased risk of cancer. Doctors must screen patients for cancer before starting treatment. Women who are pregnant or planning to become pregnant should not take Mavenclad. Regular blood tests to check lymphocyte counts are also required.
This approval gives patients with relapsing MS another treatment option. But it is important to understand that Mavenclad is not for everyone. If you or a loved one has MS, talk to your doctor about whether this drug might be appropriate. Your doctor can help weigh the benefits and risks based on your personal health history.